Human therapeutic antibodies constitute the industry’s fastest-growing therapeutic class. In the US, more than 500 antibodies are in various stages of clinical development, and the number of ...

Eledon Pharmaceuticals has a promising anti-CD40L antibody for organ rejection prevention in transplantation. Learn more ...

In contrast, after adding 20 mg/kg of monoclonal antibody against CD40 ligand to the regimen on days 0 and 2, we observed four thromboembolic complications in nine recipients. These included two ...

Frizzled (FZD) proteins are the principal receptors of the Wnt signaling pathway. However, whether Wnt ligands induce FZD endocytosis and degradation remains elusive. The transmembrane E3 ubiquitin ...

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

Adagene (NASDAQ:ADAG – Get Free Report) had its price objective increased by equities research analysts at HC Wainwright from $5.00 to $8.00 in a report issued on Monday,Benzinga reports. The ...

HCR-188, a clinic-ready antibody, entering first-in-human clinical studies with top-line data anticipated in the second half of 2025Building on ...

Compass Therapeutics, Inc.’s CMPX share price has surged by 14.18%, which has investors questioning if this is right time to ...

Ligand Pharmaceuticals Incorporated ... The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years ...

A webcast replay will be accessible following the live session on the Company’s website under Events.